Clinical trial
Effect of Quetiapine on Negative Symptoms and Cognition
NCT00305422 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00305422 |
|---|---|
| Title | Effect of Quetiapine on Negative Symptoms and Cognition |
| Official title | Efficacy of Quetiapine Compared to Risperidone on Negative Symptoms and Cognition With Regard to Underlying Neurobiological Mechanisms and Brain Activation. |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | Quetiapine fumarate, Risperidone |
| Enrollment | 45 |
| Start date | Nov 1, 2001 |
| Completion | Jan 1, 2003 |
| First posted | Mar 22, 2006 |
| Last update posted | Jun 11, 2009 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: